We are live on ! Find out more
RCUS icon

Arcus Biosciences
RCUS

184 hedge funds and large institutions have $1.36B invested in Arcus Biosciences in 2022 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 81 increasing their positions, 54 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

73% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 15

50% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 54

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

6% more funds holding

Funds holding: 173 → 184 (+11)

3% more capital invested

Capital invested by funds: $1.33B → $1.36B (+$35.9M)

0.4% less ownership

Funds ownership: 73.13% → 72.73% (-0.4%)

11% less call options, than puts

Call options by funds: $4.87M | Put options by funds: $5.46M

Holders
184
Holders Change
+11
Holders Change %
+6.36%
% of All Funds
3.17%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.1%
New
26
Increased
81
Reduced
54
Closed
15
Calls
$4.87M
Puts
$5.46M
Net Calls
-$588K
Net Calls Change
+$10.7M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$21.3M
2
PA
Perceptive Advisors
New York
+$17.6M
3
SI
Sofinnova Investments
California
+$10.1M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$9.5M
5
O
OrbiMed
New York
+$8.01M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$32.9M
2
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$11.2M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$10.3M
4
State Street
State Street
Massachusetts
-$7.77M
5
Morgan Stanley
Morgan Stanley
New York
-$6.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
PNC Financial Services Group
151
PNC Financial Services Group
Pennsylvania
$67K +$23.5K +888 +53%
Federated Hermes
152
Federated Hermes
Pennsylvania
$56K +$56.2K +2,124 New
Nisa Investment Advisors
153
Nisa Investment Advisors
Missouri
$49K +$978 +37 +2%
ICM
154
Islay Capital Management
Texas
$46K -$45.7K -1,727 -49%
HPC
155
HM Payson & Co
Maine
$44K +$18.5K +700 +70%
Osaic Holdings
156
Osaic Holdings
Arizona
$26K – – –
SWA
157
Sutton Wealth Advisors
Florida
$21.5K +$9.76K +369 +81%
Fifth Third Bancorp
158
Fifth Third Bancorp
Ohio
$17K – – –
CG
159
Cutler Group
California
$13K -$125K -4,718 -90%
US Bancorp
160
US Bancorp
Minnesota
$13K +$820 +31 +7%
WFA
161
Wipfli Financial Advisors
Wisconsin
$11K +$11.2K +424 New
Carson Wealth (CWM LLC)
162
Carson Wealth (CWM LLC)
Nebraska
$10K +$8.46K +320 +438%
AWM
163
Activest Wealth Management
Florida
$8K – – –
NCA
164
New Century Advisors
Maryland
$8K +$7.62K +288 New
O
165
OrbiMed
New York
$7.93K +$8.01M +303,000 New
QCG
166
Quadrant Capital Group
Ohio
$6K +$5.9K +223 +1,239%
PFBT
167
Parkside Financial Bank & Trust
Missouri
$4K +$2.04K +77 +90%
National Bank of Canada
168
National Bank of Canada
Quebec, Canada
$3K – – –
GRP
169
Global Retirement Partners
California
$1K -$79 -3 -12%
BIA
170
Bell Investment Advisors
California
$1K – – –
AF
171
Allworth Financial
California
$1K +$793 +30 New
FMII
172
Farmers & Merchants Investments Inc
Nebraska
$1K +$793 +30 New
BTI
173
Blue Trust Inc
Georgia
$1K +$1.06K +40 New
AIM
174
Anchor Investment Management
South Carolina
$785 – – –
Balyasny Asset Management
175
Balyasny Asset Management
Illinois
– -$10.3M -408,122 Closed
4 5 6
7
8

RCUS Hedge Fund Activity: Q3 2022 in Review

184 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q3 2022, worth a combined $1.36B — up 2.7% from $1.33B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new RCUS positions and 15 closed out — a net gain of 11 holders — while 81 added to existing stakes and 54 trimmed.

The largest buyer was BlackRock, adding an estimated $21.3M. The largest seller was BVF Inc, cutting an estimated $32.9M.

  • 184 institutional investors held Arcus Biosciences (RCUS) as of Q3 2022, up from 173 in Q2 2022.
  • Funds reported $1.36B of Arcus Biosciences stock for Q3 2022, up 2.7% quarter-over-quarter.
  • 26 funds opened new Arcus Biosciences positions in Q3 2022 and 15 closed out, a net change of +11 holders.
  • The largest Arcus Biosciences buyer in Q3 2022 was BlackRock, an estimated $21.3M added.
  • The largest Arcus Biosciences seller in Q3 2022 was BVF Inc, an estimated $32.9M sold.

Based on aggregated 13F filings for Q3 2022.